Open AccessCollagenase Clostridium Histolyticum for the Treatment of Edematous Fibrosclerotic Panniculopathy (Cellulite): A Randomized Trial
Author(s) -
Neil S. Sadick,
Mitchel P. Goldman,
Genzhou Liu,
Neil H. Shusterman,
Michael McLane,
David Hurley,
V. Leroy Young
Publication year - 2019
Publication title -
dermatologic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.659
H-Index - 125
eISSN - 1524-4725
pISSN - 1076-0512
DOI - 10.1097/dss.0000000000001803
Subject(s) - medicine , cellulite , placebo , randomized controlled trial , buttocks , adverse effect , surgery , cellulitis , pathology , alternative medicine
Edematous fibrosclerotic panniculopathy (EFP; cellulite) is associated with thickening and contraction of collagen-rich subdermal septae. Collagenase clostridium histolyticum (CCH) may disrupt collagen-rich septae.